ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board
ProMIS Neurosciences (OTCQB: ARFXF) has appointed Drs. Guy Rouleau and Alain Dagher to its scientific advisory board, enhancing its expertise in neurodegenerative diseases. Dr. Rouleau's background includes significant research on neurological and psychiatric disorders, while Dr. Dagher specializes in movement disorders, particularly Parkinson’s Disease. This strategic move aligns with ProMIS's focus on developing antibody therapeutics targeting toxic misfolded proteins linked to diseases like Alzheimer’s and ALS, reflecting its commitment to advancing treatment options.
- Appointment of renowned experts Dr. Guy Rouleau and Dr. Alain Dagher to the scientific advisory board.
- Strengthened expertise in neurodegenerative diseases which may enhance research and development efforts.
- None.
TORONTO, Ontario and CAMBRIDGE, Mass. , Feb. 03, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Drs. Guy Rouleau and Alain Dagher to its scientific advisory board (SAB).
Dr. Guy Rouleau, MD, PhD, is Director of The Neuro (Montreal Neurological Institute-Hospital), Chair of the Department of Neurology and Neurosurgery of McGill University, Director of the Department of Neuroscience of McGill University Health Centre, and co-founder of the Tanenbaum Open Science Institute. Over the last two decades, Dr. Rouleau and his team have focused on identifying genes associated with neurological and psychiatric diseases, including autism, amyotrophic lateral sclerosis, hereditary neuropathies, epilepsy and schizophrenia, as well as providing a better understanding of the molecular mechanisms that lead to disease symptoms.
Dr. Alain Dagher, MD, has been an attending neurologist at the Montreal Neurological Institute since 1997. His clinical specialty is movement disorders, with a focus on Parkinson’s Disease. His main research interest is functional brain imaging to understand the function of the basal ganglia, frontal lobes and dopamine in reward-seeking behaviors. This research has shed light on the cognitive deficits in Parkinson’s disease, stress and anxiety, schizophrenia, drug addiction, obesity, and pathological gambling and other behavioral addictions.
“On behalf of the ProMIS executive team I am delighted to welcome Drs. Rouleau and Dagher to our scientific advisory board”, stated Dr. Neil Cashman, ProMIS Chief Scientific Officer. “Their outstanding scientific contributions to a broad area of neurodegenerative, neurological and neuropsychiatric diseases is an excellent fit with ProMIS’s technology platform and portfolio of antibodies selectively targeting the toxic, misfolded proteins that are implicated in these devastating disorders.”
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF
Visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
nick@alpineequityadv.com
Tel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
###
FAQ
What recent appointments were made at ProMIS Neurosciences?
How might the new scientific advisory board members impact ProMIS Neurosciences?
What is the focus of ProMIS Neurosciences?
